Product Name: PF-02341066 HCl (Crizotinib) Request PF-02341066
PF-02341066 Chemical Structure
Price of PF-02341066-HCLR-Enantiomer, 100%
We offer a substantial discount on larger orders,
please inquire via firstname.lastname@example.org or Fax: 1-201-884-1288 (USA Fax#)
An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.
>99% by HPLC, 100% by chiral HPLC
Room temperature for short term or -20ºC for 2 years.